Meta-Analysis
Copyright ©The Author(s) 2022.
World J Psychiatry. May 19, 2022; 12(5): 739-765
Published online May 19, 2022. doi: 10.5498/wjp.v12.i5.739
Table 1 21 studies that are included in meta-analysis for Middle East respiratory syndrome
Study ID
Ref.
Study type
Sample size
Country
Exposure
Outcome
P value
Quality assessment (NOS)
1Shin et al[36]Quantitative63KoreaMERS patientsPTSD, Sleep problem, anxiety, depression, suicidality, phobic anxiety, addiction, aggressionNot specified 7
2Um et al[37]Quantitative64KoreaMERS patients and HCWsPTSD, depressionNot specified 7
3Abolfotouh et al[38]Quantitative1031Saudi ArabiaHCWsLevel of ConcernNot specified 7
4Jung et al[39]Quantitative147KoreaHCWsPTSDNot specified 6
5Ahn et al[40]Quantitative63KoreaMERS PatientsSuicide, fatigueNot specified 6
6Lee et al[41]Quantitative52KoreaMERS PatientsDepression, PTSD, fatigueNot specified 6
7Kim et al[42]Quantitative112KoreaHCWsPTSD, burnoutNot specified 7
8Oh et al[43]Quantitative313KoreaHCWsStressStress: 0.0667
9Seo et al[44]Quantitative171KoreaHCWsBurnoutNot specified 5
10Son et al[45]Quantitative280KoreaHCWs and general publicPTSDNot specified 6
11Park et al[46]Quantitative187KoreaHCWsStress Not specified 6
12Jeong et al[24]Qualitative1692KoreaMERS patients and general publicAnxiety Not specified 7
13Al-Rabiaah et al[47]Quantitative174Saudi ArabiaGeneral publicAnxiety Not specified 7
14Park et al[48]Quantitative63KoreaMERS PatientsPTSD, depression Not specified 7
15Cho et al[49]Quantitative111Korea General publicPTSDPTSD: 0.37
16Kim et al[50]Quantitative27KoreaGeneral publicDepression Not specified 5
17Lee et al[51]Quantitative359KoreaHCWsPTSD Not specified 6
18Kim and Choi[52]Quantitative215KoreaHCWsBurnout, stressNot specified 6
19Bukhari et al[53]Quantitative386Saudi ArabiaHCWsWorryNot specified 6
20Mollers et al[54]Quantitative72NetherlandsGeneral public PTSDNot specified 5
21Kim and Choi[52]Quantitative215KoreaHCWsPTSD: 0.017PTSD: 0.0176
Table 2 39 studies that are included in meta-analysis for severe acute respiratory syndrome
Study ID
Ref.
Study type
Sample size
Country/region
Exposure
P value
Quality assessment (NOS)
1Kwek et al[20]Cross-sectional360SingaporeSARS patientsPTSD: 0.79; Depression: 0.7; Anxiety: 0.517
2Fang et al[55]Cross-sectional1278ChinaSARS patientsAnxiety: 0.291; Depression: 0.705; PTSD: 0.28
3Liang[56]Prospective cohort769China, Taiwan SARS patientsPTSD: > 0.05; Anxiety: > 0.057
4Dang et al[57]Cross-sectional549ChinaGeneral publicAnxiety: < 0.00001; Depression: 0.0003617
5Yip[58]Prospective cohort218China, Hong KongSARS patientsNot specified6
6Cheng et al[59]Cross-sectional10China, Hong KongSARS patientsAnxiety: > 0.05; Depression: > 0.055
7Wu et al[60]Cross-sectional286China, Hong KongSARS patientsPTSD: < 0.001; Depression: < 0.05; Anxiety: < 0.016
8MaK et al[61]Retrospective cohort126China, Hong KongSARS patientsNot specified5
9Lee et al[62]Cross-sectional10511China, Hong KongWere not HCWsNot specified7
10Hong et al[63]Cross-sectional1050ChinaSARS patientsPTSD: 0.03237
11Wang[64]Prospective cohort22ChinaSARS patientsNot specified4
12Hu et al[65]Cross-sectional763ChinaAttended hospital for other reasonsNot specified5
13Chen et al[66]Prospective cohort325China, TaiwanNon-infected HCWs in the largest obligatory SARS hospital, with high SARS contactAnxiety: 0.55 Depression: 0.936
14Ko et al[67]Cross-sectional72China, TaiwanGeneral public of outbreak areaDepression: 0.025
15Lee et al[21]Cross-sectional114China, Hong KongGeneral public of outbreak areaNot specified6
16Hawryluck et al[68]Cross-sectional652Canada, TorontoGeneral public of outbreak areaDepression: 0.85; PTSD: 0.827
17Liu et al[69]Cross-sectional96China, BeijingNon-infected HCWs of SARS hospitalDepression: < 0.057
18Su et al[70]Prospective cohort57China, TaiwanNon-infected HCWs in SARS outbreak region with high exposure risk vs low exposure riskPTSD: > 0.05; Depression: < 0.057
19Lam et al[71]Retrospective cohort116China, Hong KongSARS patientsNot specified6
20Shi et al[72]Prospective cohort87China, BeijingSARS outbreak regionNot specified5
21Huang et al[73]Cross-sectional4481China, BeijingWere not HCWsNot specified6
22Yu et al[74]Prospective cohort180China, Hong KongGeneral public of outbreak areaNot specified5
23Chang and Sivam[75]Cross-sectional146SingaporeGeneral public of outbreak areaNot specified5
24Moldofsky and Patcai[76]Retrospective cohort107Canada, TorontoSARS patients, who were HCWsNot specified6
25Sun et al[77]Prospective cohort1557China, XianxiSARS patientsPTSD: 0.677
26Lau et al[78]Cross-sectional333China, Hong KongGeneral public of outbreak areaNot specified5
27Reynolds et al[79]Cross-sectional89CanadaGeneral public of outbreak area, quarantined; non-infected HCWs in SARS outbreak region, quarantinedNot specified5
28Lancee et al[80]Cross-sectional613Canada, TorontoNon-infected HCWs in SARS outbreak regionNot specified6
29Lin et al[81]Cross-sectional6280China, Taiwan, TaichungNon-infected HCWs in in region without major SARS outbreakNot specified6
30Gao et al[82]Prospective cohort127China, TianjinSARS patientsNot specified5
31Xu et al[83]Cross-sectional129China, XianxiNon-infected HCWs in SARS hospitalPTSD: > 0.056
32Wong et al[84]Cross-sectional0 (?)China, Hong KongNon-infected HCWs from SARS hospitalsNot specified4
33Sim et al[85]Cross-sectional90SingaporeNon-infected HCWs in SARS outbreak regionNot specified5
34Wu et al[19]Cross-sectional133China, BeijingNon-infected HCWs in SARS hospitalNot specified6
35Chen et al[86]Cross-sectional103China, Taiwan, KaohsiungNon-infected HCWs in SARS hospital, with high SARS contact; non-infected HCWs in SARS hospital; with low SARS contactNot specified6
36Tham et al[87]Cross-sectional90SingaporeNon-infected HCWs in SARS hospital with extra risk of exposureNot specified5
37Maunder et al[88]Cross-sectional90Canada, TorontoNon-infected HCWs of outbreak area, unspecified (mix of SARS affected and non SARS affected hospitalsPTSD: < 0.017
38Mak et al[89]Retrospective cohort126China, Hong KongSARS patientNot specified6
39McAlonan et al[90]Cross-sectional0 (?)China, Hong KongNon-infected HCWs in SARS outbreak region with high exposure risk vs low exposure riskNot specified3
Table 3 Pooled prevalence and confidence interval of anxiety across Middle East respiratory syndrome coronavirus, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus-2
Anxiety
Prevalence (%)
95%CI
Heterogeneity I2 (%)
MERS17.358.36-36.0295.62
SARS-CoV-221.4818.68-24.7199.76
SARS-CoV25.2018.41-34.593.47
Table 4 Pooled prevalence and confidence interval of depression across three diseases
Depression
Prevalence (%)
95%CI
Heterogeneity I2 (%)
MERS33.6522.02-51.4269.86
SARS-CoV-227.6424.59-31.0699.69
SARS-CoV23.1018.14-29.495.03
Table 5 Pooled prevalence and confidence interval of post-traumatic stress disorder across three diseases
PTSD
Prevalence (%)
95%CI
Heterogeneity I2 (%)
MERS35.9729.6-43.7275.2
SARS-CoV-225.0318.15-34.5199.58
SARS-CoV18.2014.94-22.1891.37
Table 6 Subgroup analysis on Middle East respiratory syndrome data based on different age groups
Subgroup-ageMERS

Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety10-19---
20-29---
30-39---
40-4918.518.11-42.2396.43
50-59---
Depression20-29---
30-39---
40-4938.4525.81-57.2660.55
50-59---
PTSD20-2949.7038.2-64.670
30-3919.3214.82-25.180
40-4926.6913.21-53.9180.63
50-59---
60-6917.8712.4-25.740
Table 7 Subgroup analysis on severe acute respiratory syndrome coronavirus-2 data based on different age groups
Subgroup-age
SARS-CoV-2

Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety10-1934.4033.17-35.680
20-2925.7019.38-34.0899.25
30-3922.8617.86-29.2699.64
40-4915.599.65-25.1799.66
50-5920.1310.43-38.8499.42
60-697.750.79-76.2999.47
Depression10-1943.9142.12-45.770
20-2931.0324.04-40.0499.12
30-3930.425.15-36.7499.48
40-4920.013.26-30.1899.4
50-5919.9815.84-25.1992.68
60-694.933.45-7.0590.00
PTSD20-2932.406.54-160.4998.29
30-3921.9612.77-37.7899.33
40-4927.7219.88-38.6697.59
50-595.383.76-7.690
60-69---
Table 8 Subgroup analysis on severe acute respiratory syndrome coronavirus data based on different age groups
Subgroup-ageSARS-CoV

Prevalence (%)
95%CI
Heterogeneity I2 (%)
Anxiety10-19---
20-29---
30-3924.6013.29-45.5585.81
40-4915.6310.97-22.2660.57
50-5951.6238.53-69.160
Depression20-29---
30-3927.4716.09-46.989.58
40-4920.3013.36-30.8581.57
50-5922.4914.8-34.170
60-6925.8517.69-37.750
PTSD20-2924.4315.53-38.4472.18
30-3932.1323.1-44.6889.33
40-4911.688.45-16.1586.20
50-5967.8043.57-1000
60-697.542.64-21.5453.28
Table 9 Subgroup analysis on Middle East respiratory syndrome data based on different type of people
Subgroup-occupationMERS

Prevalence (%)
95%CI
Heterogeneity I2 (%)
AnxietyGeneral Public6.042.86-12.7993.9
HCW---
Patient33.9520.65-55.8268.57
DepressionGeneral Public40.7018.89-87.710
HCW20.5211.81-35.6741.71
Patient41.6923.73-73.2271.77
PTSDGeneral Public19.0214.01-25.810
HCW49.8745.09-55.160
Patient37.7027.47-51.740
Table 10 Subgroup analysis on severe acute respiratory syndrome coronavirus-2 data based on different type of people
Subgroup-occupationSARS-CoV-2

Prevalence (%)
95%CI
Heterogeneity I2 (%)
AnxietyGeneral Public21.1817.88-25.0999.82
HCW22.3517.42-28.6699.36
Patient---
DepressionGeneral Public27.623.36-32.2499.8
HCW27.7123.22-33.0898.79
Patient---
PTSDGeneral Public24.8314.97-41.1899.67
HCW25.1616.62-38.0899.33
Patient---
Table 11 Subgroup analysis on studies under severe acute respiratory syndrome coronavirus data based on different type of people
Subgroup-occupationSARS-CoV

Prevalence (%)
95%CI
Heterogeneity I2 (%)
AnxietyGeneral Public26.1911.93-57.4898.22
HCW98.4422.67-427.490
Patient24.2117.34-33.7985.16
DepressionGeneral Public23.3114.64-37.1197.97
HCW25.4213.74-47.0390.29
Patient21.9616.86-28.678.1
PTSDGeneral Public18.3613.59-24.8181.69
HCW16.9712.28-23.4591.8
Patient19.8014.28-27.4690.44
Table 12 Sensitivity analysis for anxiety and depression studies under severe acute respiratory syndrome coronavirus-2

Exposure
Outcome
Prevalence with 95%CI (before)
Prevalence with 95%CI (after)
P value
(g)SARS-CoV-2Anxiety21.48 (18.66-24.71)25.82 (23.98-27.8)< 0.05
(h)SARS-CoV-2Depression27.64 (24.59-31.06)29.3 (26.98-31.81)> 0.05